Key result
PCSK9 inhibitors lower LDL cholesterol by ~60% on top of high-intensity statins.
Answers are grounded in this paper and cite their sources.
Some patients do not reach target low-density lipoprotein (LDL) cholesterol levels despite receiving treatment with high-intensity statins. Monoclonal antibodies that inhibit proprotein convertase subtilisin–kexin type 9 (PCSK9) have emerged as an effective treatment to address this gap and can lower LDL cholesterol by approximately 60% among patients who are already receiving standard therapy.1,2 PCSK9 is secreted by the liver and is found in 1 in every 500 LDL particles in the circulation. When these PCSK9-associated particles bind to the LDL receptor, the complex is internalized and the receptor is targeted for degradation rather than recycling back to the cell surface.3 . . .
No takes yet. Share an insight, caveat, or question.
Burnett et al. (2018) conducted an editorial in Elevated low-density lipoprotein (LDL) cholesterol. Monoclonal antibodies inhibiting PCSK9 vs. Standard therapy (high-intensity statins) was evaluated on LDL cholesterol reduction. Monoclonal antibodies inhibiting PCSK9 lower LDL cholesterol by approximately 60% among patients already receiving standard high-intensity statin therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: